Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity.

Johnson SE, Ugolkov A, Haney CR, Bondarenko G, Li L, Waters EA, Bergan R, Tran A, O'Halloran TV, Mazar A, Zhao M.

Clin Cancer Res. 2019 Feb 15;25(4):1331-1342. doi: 10.1158/1078-0432.CCR-18-1846. Epub 2018 Nov 12.

PMID:
30420445
2.

Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer.

Ugolkov AV, Matsangou M, Taxter TJ, O'Halloran TV, Cryns VL, Giles FJ, Mazar AP.

Oncol Lett. 2018 Nov;16(5):6437-6444. doi: 10.3892/ol.2018.9483. Epub 2018 Sep 21.

3.

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.

Romero-Calvo I, Weber CR, Ray M, Brown M, Kirby K, Nandi RK, Long TM, Sparrow SM, Ugolkov A, Qiang W, Zhang Y, Brunetti T, Kindler H, Segal JP, Rzhetsky A, Mazar AP, Buschmann MM, Weichselbaum R, Roggin K, White KP.

Mol Cancer Res. 2019 Jan;17(1):70-83. doi: 10.1158/1541-7786.MCR-18-0531. Epub 2018 Aug 31.

PMID:
30171177
4.

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP.

Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652.

PMID:
29846250
5.

Macrogenomic engineering via modulation of the scaling of chromatin packing density.

Almassalha LM, Bauer GM, Wu W, Cherkezyan L, Zhang D, Kendra A, Gladstein S, Chandler JE, VanDerway D, Seagle BL, Ugolkov A, Billadeau DD, O'Halloran TV, Mazar AP, Roy HK, Szleifer I, Shahabi S, Backman V.

Nat Biomed Eng. 2017 Nov;1(11):902-913. doi: 10.1038/s41551-017-0153-2. Epub 2017 Nov 6.

6.

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.

Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ.

Oncotarget. 2017 Nov 11;8(70):114924-114934. doi: 10.18632/oncotarget.22414. eCollection 2017 Dec 29.

7.

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.

Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP.

Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30.

8.

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP.

Clin Cancer Res. 2017 Apr 15;23(8):1891-1897. doi: 10.1158/1078-0432.CCR-15-2240. Epub 2017 Jan 4. Review.

9.

GSK-3 inhibition overcomes chemoresistance in human breast cancer.

Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP.

Cancer Lett. 2016 Oct 1;380(2):384-92. doi: 10.1016/j.canlet.2016.07.006. Epub 2016 Jul 14.

10.

Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated Fibroblasts.

Nwani NG, Deguiz ML, Jimenez B, Vinokour E, Dubrovskyi O, Ugolkov A, Mazar AP, Volpert OV.

Cancer Res. 2016 Apr 15;76(8):2265-76. doi: 10.1158/0008-5472.CAN-15-2468. Epub 2016 Feb 26.

11.

Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.

Gaisina IN, Tueckmantel W, Ugolkov A, Shen S, Hoffen J, Dubrovskyi O, Mazar A, Schoon RA, Billadeau D, Kozikowski AP.

ChemMedChem. 2016 Jan 5;11(1):81-92. doi: 10.1002/cmdc.201500456. Epub 2015 Nov 23.

12.

Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors.

Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskyi O, Gursel D, Mathews J, O'Halloran TV, Wei JJ, Mazar AP.

Neoplasia. 2015 Sep;17(9):735-741. doi: 10.1016/j.neo.2015.09.004.

13.

ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.

Malin D, Strekalova E, Petrovic V, Rajanala H, Sharma B, Ugolkov A, Gradishar WJ, Cryns VL.

Oncogene. 2015 Nov 5;34(45):5626-34. doi: 10.1038/onc.2015.12. Epub 2015 Feb 16.

14.

Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars.

Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, Mantis C, Ugolkov A, Mazar AP, Odom TW.

Nanomedicine. 2015 Apr;11(3):671-9. doi: 10.1016/j.nano.2014.10.005. Epub 2014 Nov 18.

15.

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP.

PLoS One. 2014 Jan 21;9(1):e85349. doi: 10.1371/journal.pone.0085349. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99911.

16.

αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, Shusta EV, Anders CK, Cryns VL.

Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.

17.

Biomimetic, synthetic HDL nanostructures for lymphoma.

Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, Ugolkov AV, Singh AT, Dave SS, Gordon LI, Thaxton CS.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2511-6. doi: 10.1073/pnas.1213657110. Epub 2013 Jan 23.

18.

Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer.

Toft DJ, Moyer TJ, Standley SM, Ruff Y, Ugolkov A, Stupp SI, Cryns VL.

ACS Nano. 2012 Sep 25;6(9):7956-65. Epub 2012 Aug 28.

19.

GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).

Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K, Naito S, Nagaoka A, Kato T, Tomita Y.

Biochem Biophys Res Commun. 2012 Jul 6;423(3):490-5. doi: 10.1016/j.bbrc.2012.05.147. Epub 2012 Jun 5.

PMID:
22683636
20.

The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.

Sakurai T, Bilim VN, Ugolkov AV, Yuuki K, Tsukigi M, Motoyama T, Tomita Y.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):607-14. doi: 10.1016/j.bbrc.2012.05.035. Epub 2012 May 15.

21.

Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.

Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, Budunova I.

Cell Cycle. 2012 Jan 15;11(2):395-406. doi: 10.4161/cc.11.2.18945. Epub 2012 Jan 15.

22.

Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3β.

Tsukigi M, Bilim V, Yuuki K, Ugolkov A, Naito S, Nagaoka A, Kato T, Motoyama T, Tomita Y.

Cancer Lett. 2012 Feb 28;315(2):189-97. doi: 10.1016/j.canlet.2011.10.008. Epub 2011 Oct 10.

PMID:
22093618
23.

Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.

Zhang JS, Koenig A, Harrison A, Ugolkov AV, Fernandez-Zapico ME, Couch FJ, Billadeau DD.

Oncogene. 2011 Aug 25;30(34):3705-15. doi: 10.1038/onc.2011.90. Epub 2011 Mar 28.

24.

Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer.

Naito S, Bilim V, Yuuki K, Ugolkov A, Motoyama T, Nagaoka A, Kato T, Tomita Y.

Clin Cancer Res. 2010 Nov 1;16(21):5124-32. doi: 10.1158/1078-0432.CCR-10-0275. Epub 2010 Oct 1.

25.

Expression analysis of putative stem cell markers in human benign and malignant prostate.

Ugolkov AV, Eisengart LJ, Luan C, Yang XJ.

Prostate. 2011 Jan 1;71(1):18-25. doi: 10.1002/pros.21217.

PMID:
20583131

Supplemental Content

Loading ...
Support Center